Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: An open-label, three-arm, randomized controlled Phase II trial

Daniel P. Petrylak, Scott T. Tagawa, Manish Kohli, Andrea Eisen, Christina Canil, Srikala S. Sridhar, Alexander Spira, Evan Y. Yu, John M. Burke, David Shaffer, Chong-Xian Pan, Jenny J. Kim, Jeanny B. Aragon-Ching, David I. Quinn, Nicholas J. Vogelzang, Shande Tang, Hui Zhang, Christopher T. Cavanaugh, Ling Gao, John S. KauhRichard A. Walgren, Kim N. Chi

Research output: Contribution to journalArticlepeer-review

60 Scopus citations

Fingerprint

Dive into the research topics of 'Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: An open-label, three-arm, randomized controlled Phase II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences